ABSTRACT Although Cl-inhibitor 
INTRODUCTION
Human plasma kallikrein, a serine protease, has a central role in the contact phase activation of blood coagulation, fibrinolysis, and kinin formation (1, 2) . Studies using plasma fractions or purified proteins have indicated that kallikrein can be inactivated by several plasma protease inhibitors, including CI-inhibitor (CI-INH)', a2 macroglobulin (a2M), antithrombin III, a2-protease inhibitor (3) (4) (5) (6) (7) (8) (9) (10) (11) . Using purified kallikrein and inhibitors, we have recently examined the kinetics of the inactivation of kallikrein by CI-INH, a2M, antithrombin III, and a,-protease inhibitor (12, 13) . Our results, together with the study of a2-plasmin inhibitor by Saito et al. (11) , indicate that C1-INH and a2M are respectively 19 and 13 times more efficient, on a molar basis, than antithrombin III, al-protease inhibitor, and a2-plasmin inhibitor combined (13) .
Less information is available on the inactivation of kallikrein in plasma, which however is a more relevant issue for the understanding of the regulation of the plasma kinin-forming system. Two reports suggest that CI-INH is the most important inhibitor of kallikrein in plasma, because the plasma of patients with hereditary angioedema possesses little inhibitory activity toward the esterolytic activity of the enzyme (5, 14) . A third paper indicates that a2M is a major inhibitor of kallikrein in plasma, because the residual arginineesterase activity present in normal plasma (37%), 5 min after plasma activation by kaolin, is not inhibitable by soybean trypsin inhibitor (6) . This same investigator shows that kallikrein, when bound to a2M, retains 48% of the esterolytic activity of the free enzyme (6) . These data suggest that a2M might account for 79% of the inactivation of kallikrein in normal plasma, and CI-INH for <21%. Thus, although these studies clearly establish that CI-INH and a2M are both significant inhibitors of kallikrein in plasma, the respective contribution of each inhibitor was not determined, nor was the relative contribution of the other inhibitors of kallikrein. One problem in determining the relative contribution of these inhibitors has been the lack of a plasma selectively deficient in a2M.
Our study is designed to assess the respective contribution of the different plasma protease inhibitors to the inactivation of kallikrein in plasma. The use of a new technique that selectively inactivates a2M in plasma facilitates the comparison of the kinetics of kallikrein inactivation. Furthermore, we quantify the concentration of each kallikrein-inhibitor complex, following the complete inactivation of the enzyme in normal plasma, as well as in the plasma cogenitally deficient or depleted of one or more protease inhibitors. CI-INH was prepared as described elsewhere (12) . The resultant preparation, M, of 105,000 on reduced and unreduced SDS-PAGE, was 97% active as determined by the method of Levy and Lepow (19) , compared with its antigenic reactivity, assessed by electroimmunodiffusion (20) .
METHODS
a2M was purified by a modification (21) of the method described by Song et al. (22) . The preparation migrated as a single band of Mr = 185,000 on reduced SDS-PAGE. 1 mg of a2M inactivated 78 yg of trypsin, as assessed by the Remazol brilliant Blue-hide assay (23) , indicating that it was fully active. The concentration of trypsin was measured by active site titration (24) Inactivation of kallikrein by normal plasma or by plasma deficient in protease inhibitors: kinetic studies. The kinetics of the inactivation of kallikrein amidolytic activity by normal plasma (Fig. 2a) is contrasted with the kinetics observed with plasma deficient in a2M (Fig. 2b ), C1-INH ( Fig. 2c ), or both inhibitors (Fig. 2d ). Cl-INH-deficient plasma was obtained from an individual with hereditary angioedema. a2M-deficient plasma was generated by incubating normal plasma with methylamine at a final concentration of 40 mM for 2 h at 23°C. Plasma deficient in both inhibitors was obtained by methylamine-treatment of the plasma from an individual with hereditary angioendema. The inactivation of kallikrein by a2M-deficient plasma (Fig. 2b ) and by plasma deficient in both inhibitors (Fig. 2d ) followed first-order kinetics. In contrast, curvilinear patterns of inhibition were seen, when functional a2M was present, as in normal plasma (Fig. 2a) (12), whereas the inactivation rate of kallikrein by a2M is hyperbolic function of the inhibitor concentration (13) . Therefore, at low concentrations of plasma, the contribution of a2M will predom- 
o The observed pseudo-first order rate constants k,,,, were derived using the data presented in Fig. 2 . The theoretical pseudo-firstorder rate constants, kther, were calculated using kinetic constants described elsewhere (11, 12)2 and inhibitor concentrations as in the experimental conditions of Fig. 2 .
inate, whereas at higher concentrations C1-INH will provide the majority of the inhibitory activity. Inactivation of kallikrein by normal plasma and by plasma deficient in protease inhibitors: gel filtration studies. To confirm the preponderant importance of CI-INH and a2M as kallikrein inhibitors in normal plasma, additional experiments were designed where 1251-kallikrein was completely inactivated in various plasma. The resulting mixtures were then analyzed by gel filtration for the appearance of 1251-kallikrein-inhibitor complexes. 1-1.4 ,ugl25I-kallikrein was used for each experiment. Purified 1251-kallikrein behaved as a single symmetric component (Fig. 3a) of Mr = 85,000. When 1251-kallikrein was preincubated with normal plasma until the inhibition reached a maximum, and then gel filtered, 32% of the radioactivity was associated with a peak of apparent Mr = 850,000, 35% was associated with a peak of apparent Mr = 370,000, while 32% remained at a Mr of 85,000 (Fig.   3B ). The M, in this experiment as well as those in Figs. 4-6 were determined by a calibration curve constructed with normal plasma. Three peaks were identified by absorbance at 280 nm and used as internal standards: IgM (Mr = 900,000), IgG (M, = 160,000), 3 Gel filtration of 1251-kallikrein alone or with normal plasma. 2 ml of the mixture generated after a 2-h incubation at 37°C of (A) 1251-kallikrein (0.2 ml) and 1.8 buffer, or (B) 1251-kallikrein (0.2 ml) and normal human plasma (1.8 ml) were separated by gel filtration on Sepharose CL 6B at 23°C in 0.1 M sodium phosphate, pH 7.6, containing 0.15 M NaCl, 1% bovine serum albumin, and 0.02% sodium azide. 1-ml fractions were collected. Column: 1.6 X 95 cm. Flow rate: 8 ml/min. and albumin (M, = 68,000). The log M, was plotted versus fraction number and unknown Mr interpolated.
To characterize the radioactive peaks formed as a result of the inactivation of '251-kallikrein in normal plasma, the gel filtration behavior of complexes of purified components was determined. Preformed 1251_ kallikrein-C I-INH and '251-kallikrein-a2M complexes were gel filtered ( Fig. 4A and 4B) (13) . However, the active enzyme was entirely complexed to the inhibitor because this amidolotic activity was not inhibitable by soybean trypsin inhibitor. Therefore, it appeared that the inactivation of kallikrein in normal plasma (Fig. 3B) resulted almost exclusively in the formation of complexes with molecular weights characteristic of kallikrein-C I-INH and kallikrein-a2M complexes. Moreover, a similar amount of enzyme was complexed to CI-INH and to a2M (Fig. 3B ). 4 Gel filtration of '251-kallikrein after interaction with purified CI-INH or a2M. 2 ml of the mixture generated after a 2-h incubation at 37°C of (A) 1251-kallikrein and CI-INH and (B) 1251-kallikrein and a2M were gel filtered as described in Fig. 3 . CI-INH final concentration: 6.8 ,uM. Alpha-2-macroglobulin final concentration: 3.5 uM.
To further confirm these results, '251-kallikrein was incubated with a2M-deficient or CI-INH-deficient plasma. Analysis of the resultant mixtures revealed that the Cl-INH-kallikrein complex was the only detectable enzyme-inhibitor complex in a2M-deficient plasma (Fig. 5A) , whereas the a2M-kallikrein complex was the only observed complex involving kallikrein in Cl-INH-deficient plasma (Fig. 5B) . Indeed, the pattern observed when kallikrein was incubated with a2M-deficient plasma (Fig. 5A) closely resembled the complex of purified CI-INH with kallikrein (Fig. 4A) . Similarly, the pattern observed when kallikrein was incubated with CI-INH-deficient plasma (Fig. 5B) closely resembled the complex of purified a2M with kallikrein (Fig. 4B) .
To demonstrate the existence of minor inhibitor(s) of kallikrein in plasma, 125I-kallikrein was then completely inhibited in the methylamine-treated plasma of an individual with hereditary angioedema, i.e., in plasma deficient in both C1-INH and a2M. The resultant mixture was then gel filtered and analyzed for radioactivity (Fig. 6) . 67% of the label was found to be associated to a peak of apparent M, = 185,000. 5 Gel filtration of '251-kallikrein with plasma deficient at a2M or CI-INH. 2 ml of the mixture generated after a 2-h incubation at 37-C of (A) 1251-kallikrein and a2M-deficient plasma and (B) '251-kallikrein and CI-INH deficient plasma were gel filtered as described in Fig. 3. significantly the inactivation rate of kallikrein by these inhibitor(s) and therefore increase the amount of enzyme complexed to these inhibitor(s), '251-kallikrein was inactivated in CI-INH deficient, or in a2M deficient plasma, respectively, after these plasmas were adjusted to contain 2 U/ml with heparin. The resultant chromatograms (not shown) were identical to those illustrated in Fig. 5A and B.
DISCUSSION
The results obtained in this study indicate that CI-INH and a2M are the major inhibitors of kallikrein in normal human plasma. This conclusion is supported by (a) the analysis of the kinetics of kallikrein inactivation in normal and protease inhibitor-deficient plasma, and (b) by the quantitation upon gel filtration of the kallikrein-inhibitor complexes formed in plasma as the result of the inactivation of purified radiolabeled enzyme.
Because no complete deficiency of a2M has been documented in human plasma, quantitative assessment of the role of this inhibitor in plasma has been difficult. The discovery that methylamine can inactivate the purified inhibitor, most likely by scission of a thiolester reactive site (25, 26) , led us to assess the effect of this nucleophilic agent in plasma. Kinetic observations, including the elimination of the characteristic curvilinear inhibition profile, indicate that methylamine is just as effective in plasma as in purified systems. Moreover, although it can modify other plasma proteins, notably C3 and C4 (27, 28) , it does not inactivate CI-INH (Fig. 1 ).
Kinetic studies revealed that the rate constant of kallikrein inactivation by plasma deficient either in CJ-INH, or in a2M, was reduced to 50% of the rate constant observed when kallikrein was inactivated by normal plasma (Fig. 2) . Thus, CI-INH and a2M each contributed equally to the inactivation rate constant of the enzyme in normal human plasma (Fig. 2) . Moreover, the inactivation rate constant of kallikrein by normal plasma was accurately predicted by adding the theoretical contributions of CI-INH and a2M, assessed by studies in purified systems (Table I ). This observation indicates that these inhibitors act independently in the inactivation of the enzyme. This finding is not surprising because CI-INH is a competitive inhibitor of kallikrein and a2M is a noncompetitive one (13) . When kallikrein was inactivated by plasma deficient in both C1-INH and a2M, its inactivation rate constant was only 10% of the rate constant observed in normal plasma. This observation indicated that all the other plasma protease inhibitors contributed only marginally to the inactivation of kallikrein in normal plasma.
To independently assess the role of C1-INH and a2M in the inactivation of kallikrein, '25I-kallikrein was incubated with normal and deficient plasma until complete inactivation, and the resulting mixtures were analysed by gel filtration for the formation of enzymeinhibitor complexes. The radiolabeled kallikrein used in these experiments was 67-69% active, as assessed by its ability to form complexes with purified a2M or C1-INH. This value is similar to that obtained for other proteolytic enzymes such as trypsin (29) by active site titration. In the mixture resulting from the incubation of kallikrein with normal plasma, 52% of the active enzyme was associated with CI-INH and 48% with a2M (Fig. 3B) . The difference between these results and those of Harpel (6) could result from the fact that in that study kallikrein was activated endogenously by adding kaolin to plasma whereas in this study preformed kallikrein was added to plasma. Such a difference has been recently reported for the distribution of plasmin between its plasma inhibitors (30) . Additional experiments, where kallikrein was incubated with plasma deficient in protease inhibitors, revealed that >90% of the active enzyme was associated with CI-INH in plasma deficient in a2M (Fig. 5A) , while a similar proportion of active kallikrein was associated to a2M in Cl-INH-deficient plasma (Fig. 5B) . These experiments confirmed the preponderent role of C1-INH and a2M for the inactivation of kallikrein in plasma.
In the absence of either C1-INH or a2M, almost all the active enzyme was complexed to the other major inhibitor. The apparent M, for the a2M-kallikrein complex was 850,000 daltons close to the predicted value of 813,000 (725,000 + 88,000). However, the apparent M, for the kallikrein C1-INH complex was 370,000 daltons, exceeding the predicted value of 193,000 (105,000 + 88,000). This finding suggested that the kallikrein-C 1-INH complex might have a high frictional ratio with a more assymetric shape than either of its components.
Finally, minor inhibitors of kallikrein were observed, using the gel filtration technique but only after the enzyme had been inactivated in plasma deficient both in Ci-INH and a2M (Fig. 6 ). The M, of the kallikrein-inhibitor complex(es) was 185,000, indicating that antithrombin III, a2M-plasmin inhibitor, and/or a1-antitrypsin may be part of these complexes (31) . Because these complex(es) were clearly identifiable only in the absence of both major inhibitors, this experiment confirmed that the reaction of kallikrein with its other plasma protease inhibitors was significantly slower than its reaction with either C1-INH or a2M.
The plasma used in the gel filtration experiments were almost undiluted, in contrast to the plasma used for kinetic experiments, which was diluted 1:8. 6 Gel filtration of '25I-kallikrein with plasma deficient in both a2M and CL-INH. 2 ml of the mixture generated after a 2-h incubation at 370C of 1251-kallikrein and plasma deficient in both C1-INH and a2M were gel filtered as described in Fig. 3 .
derived from studies in purified systems (13) (14) (15) . This observation validates the use of these kinetic constants for the determination of the fluid phase kallikrein inactivation rate in systems containing the concentration of protease inhibitors present in normal plasma.
We have recently reported that the rate of kallikrein inactivation was reduced by the presence of the contact phase cofactor high molecular weight kininogen (12) . This reduction in inactivation rate was the result of the formation of a reversible complex, Kd = 0.75 AM, between kallikrein and high molecular weight kininogen. The protective role of high molecular weight kininogen was ignored in the kinetic experiments described in the present report, because the concentration of this cofactor in the preincubation mixture was only 0.08 ,M. At this concentration, high molecular weight kininogen is expected to decrease the inactivation rate of kallikrein by only 10% (12) . Moreover, the influence of high molecular weight kininogen was not detectable in the gel filtration experiments, which were performed after complete inactivation of the enzyme because the cofactor decreases the rate but not the extent of kallikrein inactivation (12, 32) . For analysis of -the rate of kallikrein inactivation in vivo, it is however clear that the protective effect of high molecular weight kininogen should be considered.
Inactivation of Kallikrein in Plasma 467
